巩固治疗史对首次完全缓解且微小残留病阴性的急性髓系白血病患者接受异基因造血细胞移植的预后意义
本研究回顾性分析在本机构2003年1月至2016年4月间接受异基因造血细胞移植、移植时微小残留病阴性且处于首次完全缓解的急性髓系白血病患者,探讨既往巩固治疗史是否提供额外预后信息。结果显示有巩固治疗史与更优的总生存、无复发生存及更低复发相关,作者认为该结果需在更大队列中验证。
要点
- 在微小残留病阴性首次完全缓解的急性髓系白血病移植患者中,既往巩固治疗史与更优生存和更低复发相关。
- 有巩固治疗史者总生存风险比0.59(95%CI 0.35-0.99,P=.046),无复发生存风险比0.60(95%CI 0.37-0.96,P=.036)。
- 有巩固治疗史者复发风险比0.50(95%CI 0.27-0.92,P=.025)。
核心结论
- 在微小残留病阴性首次完全缓解的急性髓系白血病患者中,接受异基因造血细胞移植前有巩固治疗史与更优的移植后结局相关。
- 若达到移植前微小残留病阴性的路径中包含巩固治疗,可能识别出移植后预后更佳的患者。
- 作者指出这些结果需在更大队列中验证。
研究设计与样本
- 回顾性研究,纳入2003年1月至2016年4月在本机构接受异基因造血细胞移植的患者。
- 纳入标准为年龄大于18岁、经1-2个周期强化诱导化疗后处于首次完全缓解(伴或不伴巩固治疗)、移植前一个月内完成所有既往化疗后骨髓穿刺的四色流式细胞术标准敏感性检测结果可用、移植时流式细胞术微小残留病阴性。
- 研究探讨既往巩固治疗史是否提供额外预后信息。
主要发现
- 有巩固治疗史与更优的总生存相关:风险比0.59(95%CI 0.35-0.99,P=.046)。
- 有巩固治疗史与更优的无复发生存相关:风险比0.60(95%CI 0.37-0.96,P=.036)。
- 有巩固治疗史与更低的复发相关:风险比0.50(95%CI 0.27-0.92,P=.025)。
- 对潜在偏倚来源的分析未发现异常。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文为回顾性研究。
- 作者指出这些结果需在更大队列中验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Prognostic factors among acute myeloid leukemia (AML) patients undergoing allogeneic hematopoietic cell transplantation (allo-HCT) in minimal residual disease (MRD)-negative first complete remission (CR1) are unknown. We retrospectively attempted to answer the following question: In AML patients undergoing allo-HCT in MRD-negative CR1, does a history of prior consolidation provide additional prognostic information? METHODS: The inclusion criteria were: (i) Age > 18 years, (ii) AML in CR1 after 1-2 cycles of intensive induction chemotherapy, with or without consolidation, (iii) Allo-HCT between 1/2003 and 4/2016 at our institution, (iv) Available standard-sensitivity 4-color flow cytometry results from a bone marrow aspiration at diagnosis and after completion of all previous chemotherapy within one month prior to HCT, (v) Flow cytometry-based MRD-negative status at the time of HCT. RESULTS: A history of prior consolidation was associated with favorable overall survival (Hazard Ratio [95% Confidence Interval]: 0.59 [0.35-0.99], P = .046), relapse-free survival (0.60 [0.37-0.96], P = .036), and relapse (0.50 [0.27-0.92], P = .025). Analysis of potential sources of bias was unrevealing. CONCLUSIONS: In AML patients undergoing allo-HCT in MRD-negative CR1, a history of prior consolidation was associated with favorable outcomes. If the path to pre-HCT MRD negativity includes consolidation, it may identify patients with improved prognosis following HCT in MRD-negative state. These results warrant validation in larger cohorts.
引用
- Rashidi A, Linden MA, DeFor TE, et al. History of consolidation is prognostic in acute myeloid leukemia patients undergoing allogeneic hematopoietic cell transplantation in minimal residual disease-negative first complete remission. Am J Hematol. 2017. PMID: 28646534. doi:10.1002/ajh.24834
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。